

Arjen H G Cleven

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4154263/publications.pdf>

Version: 2024-02-01

38
papers

1,177
citations

567281

15
h-index

395702

33
g-index

38
all docs

38
docs citations

38
times ranked

2405
citing authors

#	ARTICLE	IF	CITATIONS
1	Mutation Analysis of H3F3A and H3F3B as a Diagnostic Tool for Giant Cell Tumor of Bone and Chondroblastoma. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1576-1583.	3.7	174
2	Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival. <i>Modern Pathology</i> , 2016, 29, 582-590.	5.5	164
3	Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 119-128.	4.2	89
4	Molecular Analysis of Gene Fusions in Bone and Soft Tissue Tumors by Anchored Multiplex PCR-Based Targeted Next-Generation Sequencing. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 653-663.	2.8	85
5	A subset of epithelioid and spindle cell rhabdomyosarcomas is associated with TFCP2 fusions and common ALK upregulation. <i>Modern Pathology</i> , 2020, 33, 404-419.	5.5	80
6	High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma. <i>Blood</i> , 2018, 131, 2086-2089.	1.4	69
7	IDH1 or -2 mutations do not predict outcome and do not cause loss of 5-hydroxymethylcytosine or altered histone modifications in central chondrosarcomas. <i>Clinical Sarcoma Research</i> , 2017, 7, 8.	2.3	50
8	Utility of FOS as diagnostic marker for osteoid osteoma and osteoblastoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 455-463.	2.8	44
9	High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome. <i>Modern Pathology</i> , 2015, 28, 552-563.	5.5	42
10	Prognostic Metabolite Biomarkers for Soft Tissue Sarcomas Discovered by Mass Spectrometry Imaging. <i>Journal of the American Society for Mass Spectrometry</i> , 2017, 28, 376-383.	2.8	37
11	Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation. <i>British Journal of Cancer</i> , 2018, 118, 1074-1083.	6.4	37
12	Increased infiltration of M2-macrophages, T-cells and PD-L1 expression in high grade leiomyosarcomas supports immunotherapeutic strategies. <i>Oncolmmunology</i> , 2018, 7, e1386828.	4.6	36
13	Periosteal chondrosarcoma: a histopathological and molecular analysis of a rare chondrosarcoma subtype. <i>Histopathology</i> , 2015, 67, 483-490.	2.9	29
14	<scp>ARTISAN PCR</scp>: rapid identification of full-length immunoglobulin rearrangements without primer binding bias. <i>British Journal of Haematology</i> , 2017, 178, 983-986.	2.5	28
15	Clinical, Histologic, and Molecular Characteristics of Anaplastic Lymphoma Kinase-positive Primary Cutaneous Anaplastic Large Cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2020, 44, 776-781.	3.7	25
16	Robust detection of translocations in lymphoma FFPE samples using targeted locus capture-based sequencing. <i>Nature Communications</i> , 2021, 12, 3361.	12.8	19
17	High frequency of inactivating tetraspanin CD37 mutations in diffuse large B-cell lymphoma at immune-privileged sites. <i>Blood</i> , 2019, 134, 946-950.	1.4	18
18	Molecular findings in maxillofacial bone tumours and its diagnostic value. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 159-174.	2.8	17

#	ARTICLE	IF	CITATIONS
19	Primary Osteosarcoma of the Breast. <i>Radiographics</i> , 2019, 39, 626-629.	3.3	14
20	<sc>DOG</sc>1 expression in giant cell containing bone tumours. <i>Histopathology</i> , 2016, 68, 942-945.	2.9	13
21	Conventional chondrosarcoma with focal clear cell change: a clinicopathological and molecular analysis. <i>Histopathology</i> , 2019, 75, 843-852.	2.9	13
22	An experimental guideline for the analysis of histologically heterogeneous tumors by MALDI-TOF mass spectrometry imaging. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2017, 1865, 957-966.	2.3	11
23	Frequent mutated <i>B2M</i>, <i>EZH2</i>, <i>IRF8</i>, and <i>TNFRSF14</i> in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype. <i>Blood Advances</i> , 2021, 5, 3760-3775.	5.2	11
24	Hematopoietic Tumors Primarily Presenting in Bone. <i>Surgical Pathology Clinics</i> , 2017, 10, 675-691.	1.7	9
25	Ossifying Fibroma of Non-odontogenic Origin: A Fibro-osseous Lesion in the Craniofacial Skeleton to be (Re-)considered. <i>Head and Neck Pathology</i> , 2022, 16, 257-267.	2.6	9
26	Identifying the culprit lesion in tumor induced hypophosphatemia, the solution of a clinical enigma. <i>Endocrine</i> , 2016, 54, 642-647.	2.3	8
27	No preclinical rationale for IGF1R directed therapy in chondrosarcoma of bone. <i>BMC Cancer</i> , 2016, 16, 475.	2.6	7
28	<i>NTRK</i> fusions are extremely rare in bone tumours. <i>Histopathology</i> , 2021, 79, 880-885.	2.9	7
29	Current Pathologic Scoring Systems for Metal-on-metal THA Revisions are not Reproducible. <i>Clinical Orthopaedics and Related Research</i> , 2017, 475, 3005-3011.	1.5	5
30	B cell lymphoblastic lymphoma with cutaneous involvement and a <sc><i>KMT2A</i></sc> gene rearrangement. <i>American Journal of Hematology</i> , 2020, 95, 1427-1429.	4.1	5
31	High nuclear expression of proteasome activator complex subunit 1 predicts poor survival in soft tissue leiomyosarcomas. <i>Clinical Sarcoma Research</i> , 2016, 6, 17.	2.3	4
32	Corresponding anaplastic lymphoma kinase tropomyosin 3 (ALK-TPM3) fusion in a patient with a primary cutaneous anaplastic large-cell lymphoma and a Spitz nevus. <i>JAAD Case Reports</i> , 2019, 5, 970-972.	0.8	4
33	Apparent Lack of BRAFV600E Derived HLA Class I Presented Neoantigens Hampers Neoplastic Cell Targeting by CD8+ T Cells in Langerhans Cell Histiocytosis. <i>Frontiers in Immunology</i> , 2019, 10, 3045.	4.8	4
34	The Influence of Personalised Sarcoma Care (PERSARC) Prediction Modelling on Clinical Decision Making in a Multidisciplinary Setting. <i>Sarcoma</i> , 2021, 2021, 1-6.	1.3	4
35	Oestrogen receptor expression distinguishes non-ossifying fibroma from other giant cell containing bone tumours. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 481, 671-675.	2.8	3
36	Synchronous diffuse large B-cell lymphoma and mantle cell lymphoma: support for low-threshold biopsies and genetic testing. <i>Leukemia and Lymphoma</i> , 2021, , 1-5.	1.3	2

#	ARTICLE	IF	CITATIONS
37	Multiple pleomorphic dermal sarcomas with metastases in an immunosuppressed patient. Dermatologic Therapy, 2020, 33, e13441.	1.7	1
38	High Frequencies of Mutated EZH2 and IRF8 and Other Epigenetic Genes in Primary Bone Lymphomas Are Indicative of GCB-Phenotype. Blood, 2019, 134, 1484-1484.	1.4	0